https://www.selleckchem.com/products/gilteritinib-asp2215.html aureus (MRSA) through membrane interactions.Antivirals have demonstrated efficacy in treating other infectious diseases in early stages of disease, reducing morbidity, mortality, and the likelihood of onward transmission. At the time of writing, more than 1900 clinical trials are registered globally to assess the efficacy and safety of candidate therapeutics for COVID-19. The majority of these trials are designed to evaluate the comparative efficacy and safety of candidate therapeutics for the treatment of COVID-19 to prevent death among populations of hospitalized patients with advanced disease. Yet, emerging epidemiological evidence now indicates that the majority of those infected with the SARS-CoV-2, while still infectious, experience minimal or mild disease symptomology. Like HIV and hepatitis C that pioneered treatment as prevention, there is a missed opportunity for trials of early pharmaceutical intervention for COVID-19 disease evaluating not only reductions in morbidity and mortality but also transmissibility. We discuss this clinical research gap within an historical context of viral treatment as prevention for HIV and hepatitis C, and comment on the challenges and opportunities for clinical research of candidate therapeutics for early COVID-19 disease.The covid-19 disease has a large impact on life across the globe, and this could potentially include impacts on crime. The present study describes how crime has changed in Sweden during ten weeks after the government started to implement interventions to reduce spread of the disease. Sweden has undertaken smaller interventions than many other countries and is therefore a particularly interesting case to study. The first major interventions in Sweden were implemented in the end of week 11 (March 12th) in the year 2020, and we analyze police reported crimes through week 21 (ending May 24th). Descriptive statistics are provided relative to expected